RT Journal Article
SR Electronic
T1 Angiotensin-receptor blockers in heart failure
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 665
OP 673
VO 71
IS 8
A1 Bhakta, Shyam
A1 Dunlap, Mark E.
YR 2004
UL http://www.ccjm.org/content/71/8/665.abstract
AB The large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. Candesartan was beneficial in heart failure patients with or without left ventricular systolic dysfunction.